269 related articles for article (PubMed ID: 34051351)
41. Gut microbiota: impacts on gastrointestinal cancer immunotherapy.
Lau HCH; Sung JJ; Yu J
Gut Microbes; 2021; 13(1):1-21. PubMed ID: 33435800
[TBL] [Abstract][Full Text] [Related]
42. The Complex Role of the Microbiome in Non-Small Cell Lung Cancer Development and Progression.
Souza VGP; Forder A; Pewarchuk ME; Telkar N; de Araujo RP; Stewart GL; Vieira J; Reis PP; Lam WL
Cells; 2023 Dec; 12(24):. PubMed ID: 38132121
[TBL] [Abstract][Full Text] [Related]
43. Microbiome as a biomarker and therapeutic target in pancreatic cancer.
Pourali G; Kazemi D; Chadeganipour AS; Arastonejad M; Kashani SN; Pourali R; Maftooh M; Akbarzade H; Fiuji H; Hassanian SM; Ghayour-Mobarhan M; Ferns GA; Khazaei M; Avan A
BMC Microbiol; 2024 Jan; 24(1):16. PubMed ID: 38183010
[TBL] [Abstract][Full Text] [Related]
44. The Role of the Microbiome in Immunologic Development and its Implication For Pancreatic Cancer Immunotherapy.
Sethi V; Vitiello GA; Saxena D; Miller G; Dudeja V
Gastroenterology; 2019 May; 156(7):2097-2115.e2. PubMed ID: 30768986
[TBL] [Abstract][Full Text] [Related]
45. Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy.
Wu J; Wang S; Zheng B; Qiu X; Wang H; Chen L
Front Immunol; 2021; 12():669150. PubMed ID: 34267748
[TBL] [Abstract][Full Text] [Related]
46. Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients.
Mohindroo C; Hasanov M; Rogers JE; Dong W; Prakash LR; Baydogan S; Mizrahi JD; Overman MJ; Varadhachary GR; Wolff RA; Javle MM; Fogelman DR; Lotze MT; Kim MP; Katz MHG; Pant S; Tzeng CD; McAllister F
Cancer Med; 2021 Aug; 10(15):5041-5050. PubMed ID: 34250759
[TBL] [Abstract][Full Text] [Related]
47. Intratumoral microbiota: A new force in diagnosing and treating pancreatic cancer.
Jiang Z; Zhang W; Zhang Z; Sha G; Wang D; Tang D
Cancer Lett; 2023 Feb; 554():216031. PubMed ID: 36481214
[TBL] [Abstract][Full Text] [Related]
48. Emerging role of microbiota in immunomodulation and cancer immunotherapy.
Singh RP; Bashir H; Kumar R
Semin Cancer Biol; 2021 May; 70():37-52. PubMed ID: 32580024
[TBL] [Abstract][Full Text] [Related]
49. The role of the microbiome in pancreatic oncogenesis.
Daley D
Int Immunol; 2022 Sep; 34(9):447-454. PubMed ID: 35863313
[TBL] [Abstract][Full Text] [Related]
50. The tumor microenvironment in pancreatic ductal adenocarcinoma: current perspectives and future directions.
Herting CJ; Karpovsky I; Lesinski GB
Cancer Metastasis Rev; 2021 Sep; 40(3):675-689. PubMed ID: 34591240
[TBL] [Abstract][Full Text] [Related]
51. [The role of the microbiome in diseases of the pancreas].
Frost F; Weiss FU; Lerch MM
Internist (Berl); 2022 Apr; 63(4):372-378. PubMed ID: 35175369
[TBL] [Abstract][Full Text] [Related]
52. The impact of tumor and gut microbiotas on cancer therapy: Beneficial or detrimental?
Hekmatshoar Y; Rahbar Saadat Y; Hosseiniyan Khatibi SM; Ozkan T; Zununi Vahed F; Nariman-Saleh-Fam Z; Pourghassem Gargari B; Sunguroglu A; Zununi Vahed S
Life Sci; 2019 Sep; 233():116680. PubMed ID: 31344431
[TBL] [Abstract][Full Text] [Related]
53. Manipulating Gut Microbiota Composition to Enhance the Therapeutic Effect of Cancer Immunotherapy.
Yi M; Jiao D; Qin S; Chu Q; Li A; Wu K
Integr Cancer Ther; 2019; 18():1534735419876351. PubMed ID: 31517538
[TBL] [Abstract][Full Text] [Related]
54. [Advances in immunotherapy of pancreatic ductal adenocarcinoma].
Yang JQ; Wei T; Chen YW; Bai XL; Liang TB
Zhonghua Wai Ke Za Zhi; 2017 May; 55(5):396-400. PubMed ID: 28464583
[TBL] [Abstract][Full Text] [Related]
55. Modulation of cancer immunotherapy efficacy by gut microbiota.
Huo S; Liu L; Liu J; Li Q; Wang J
Discov Med; 2019 Feb; 27(147):93-100. PubMed ID: 30939293
[TBL] [Abstract][Full Text] [Related]
56. Multimodal immune phenotyping reveals microbial-T cell interactions that shape pancreatic cancer.
Li Y; Chang RB; Stone ML; Delman D; Markowitz K; Xue Y; Coho H; Herrera VM; Li JH; Zhang L; Choi-Bose S; Giannone M; Shin SM; Coyne EM; Hernandez A; Gross NE; Charmsaz S; Ho WJ; Lee JW; Beatty GL
Cell Rep Med; 2024 Feb; 5(2):101397. PubMed ID: 38307029
[TBL] [Abstract][Full Text] [Related]
57. Microbiota in pancreatic health and disease: the next frontier in microbiome research.
Thomas RM; Jobin C
Nat Rev Gastroenterol Hepatol; 2020 Jan; 17(1):53-64. PubMed ID: 31811279
[TBL] [Abstract][Full Text] [Related]
58. Tumor microbiome contributes to an aggressive phenotype in the basal-like subtype of pancreatic cancer.
Guo W; Zhang Y; Guo S; Mei Z; Liao H; Dong H; Wu K; Ye H; Zhang Y; Zhu Y; Lang J; Hu L; Jin G; Kong X
Commun Biol; 2021 Aug; 4(1):1019. PubMed ID: 34465850
[TBL] [Abstract][Full Text] [Related]
59. Novel Anticancer Strategy by Targeting the Gut Microbial Neurotransmitter Signaling to Overcome Immunotherapy Resistance.
Leung EL; Huang J; Zhang J; Zhang J; Wang M; Zhu Y; Meng Z; Yu H; Neher E; Ma L; Yao X
Antioxid Redox Signal; 2023 Feb; 38(4-6):298-315. PubMed ID: 36017627
[No Abstract] [Full Text] [Related]
60. Microbiomes in pancreatic cancer can be an accomplice or a weapon.
Guo X; Wang P; Li Y; Chang Y; Wang X
Crit Rev Oncol Hematol; 2024 Feb; 194():104262. PubMed ID: 38199428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
